DPC 681 and DPC 684: Potent, Selective Inhibitors of Human Immunodeficiency Virus Protease Active against Clinically Relevant Mutant Variants

Human immunodeficiency virus (HIV) protease inhibitors (PIs) are important components of many highly active antiretroviral therapy regimens. However, development of phenotypic and/or genotypic resistance can occur, including cross-resistance to other PIs. Development of resistance takes place becaus...

Descrizione completa

Dettagli Bibliografici

Pubblicato in:	Antimicrob Agents Chemother
Autori principali:	Kaltenbach, Robert F., Trainor, George, Getman, Daniel, Harris, Greg, Garber, Sena, Cordova, Beverly, Bacheler, Lee, Jeffrey, Susan, Logue, Kelly, Cawood, Pamela, Klabe, Ronald, Diamond, Sharon, Davies, Marc, Saye, Joanne, Jona, Janan, Erickson-Viitanen, Susan
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	American Society for Microbiology (ASM) 2001
Soggetti:	Antiviral Agents
Accesso online:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC90777/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/11600351/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/AAC.45.11.3021-3028.2001
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!